Business Context and Reporting Period
Company: Impact BioMedical Inc. (IBO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Impact BioMedical discovers, patents, and licenses biopharmaceutical and wellness technologies. Key proprietary platforms include Linebacker (oncology/inflammation), Laetose (metabolic health), 3F (functional fragrances), and Equivir (antiviral). The company operates through several subsidiaries and relies on licensing agreements and potential direct sales for revenue.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $10,000 | $7,000 |
| Net Loss | $(2,983,000) | $(15,631,000) |
| Net Loss Attributable to Common Stockholders | $(2,985,000) | $(15,614,000) |
| Operating Loss | $(2,990,000) | $(2,165,000) |
| Cash and Cash Equivalents (End of Period) | $10,000 | $624,000 |
| Net Cash Provided by Operating Activities | $6,000 | $(1,376,000) |
| Total Assets | $16,745,000 | $17,405,000 |
| Total Liabilities | $2,733,000 | $1,850,000 |
| Stockholders' Equity | $14,012,000 | $15,555,000 |
Key Balance Sheet Items:
- Intangible Assets, Net: $16,425,000 (Primary asset class, consisting of developed technology and patents).
- Due to Related Party: $1,330,000 (Non-interest bearing, due on demand).
- Notes Receivable (Current): $197,000.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 81% year-over-year (from $15.6M to $3.0M). This improvement is primarily due to the absence of a $12.9M non-cash fair value adjustment on a related-party note payable that occurred in the prior year. The current period loss was partially offset by a $1.44M stock-based compensation charge.
- Revenue Growth: Revenue increased 43% to $10,000 for the six-month period, driven by retail sales of the Celios air purification system acquired in early 2025.
- Expense Fluctuations:
- Stock-Based Compensation: Increased significantly to $1.44M (from $3,000) due to the issuance of 3.2M shares to executives and board members in January 2026.
- Professional Fees: Decreased 45% to $350,000 as the company reduced external consulting and legal engagements.
- SG&A Compensation: Decreased 30% to $346,000 due to reduced employee pay and bonus accruals.
- Liquidity: Cash balance increased slightly from $3,000 to $10,000 during the period, with operating cash flow turning positive ($6,000) compared to a significant outflow in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company has incurred operating losses and negative cash flows over the past two years, raising substantial doubt about its ability to continue as a going concern within one year of the report date. Management plans to address this through capital raises (NYSE American listing), debt financing, and monetization of intellectual property.
- Capital Structure Changes: In October 2025, a significant related-party note payable (approx. $15M principal/interest) was converted into 31.9M shares of common stock. In January 2026, 3.2M shares were issued for compensation.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing material weaknesses disclosed in the prior year's 10-K that remained unremediated.
- Strategic Focus: The company is actively seeking partners for the commercialization of Laetose and 3F technologies and continues to evaluate emerging technologies in bioplastics, nanotechnology, and personalized medicine.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10,000 cash balance against current burn rates and the timeline for securing additional capital.
- Related Party Transactions: Review the $1.33M "Due to Related Party" balance and the terms of the non-interest-bearing funding from DSS (majority shareholder).
- Intangible Asset Valuation: Assess the recoverability of the $16.4M in intangible assets given the lack of significant revenue generation from these technologies.
- Internal Control Remediation: Confirm the status of remediation efforts for the material weaknesses in internal controls over financial reporting.
- Revenue Sustainability: Evaluate the scalability of the $10,000 revenue stream from Celios retail sales and the likelihood of milestone payments from licensing partners (ProPhase, Chemia).